drugset / Trial / NCT00700076
Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects
RandomizedCrossoverQuadruple-blindBasic science
Summary
Org 25935 is a new putative antipsychotic agent developed by N.V. Organon.The primary objective of this study is to investigate the effect of Org 25935 on ketamine-induced impairments in immediate recall.
Timeline
- Start
- 2008-01-22
- Primary completion
- 2009-03-09
- Completion
- 2009-03-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Org 25935 | Small molecule | 16 mg | Oral |
| Comparator | Ketamine | Small molecule | 0.29 mg/kg | Intravenous |
Indications
No indication recorded.